| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
137,030,000 |
| Market
Cap: |
6.07(B) |
| Last
Volume: |
1,182,236 |
Avg
Vol: |
1,218,005 |
| 52
Week Range: |
$32.49 - $45.82 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 466 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Halozyme Therapeutics is a biopharma technology platform company that provides solutions to improve patient experience and outcomes. Co.'s approved product and its collaborators' approved products and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. Co. refers to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as its ENHANZE® drug delivery technology (ENHANZE). Co. licenses the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
60,000 |
120,000 |
300,000 |
584,448 |
| Total Sell Value |
$2,512,970 |
$4,828,155 |
$12,314,195 |
$26,911,596 |
| Total People Sold |
1 |
1 |
3 |
6 |
| Total Sell Transactions |
6 |
12 |
30 |
61 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kirk Randal J |
Director |
– • • |
2013-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
3,470,000 |
|
- |
|
| Falberg Kathryn E |
Director |
– • – |
2013-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
180,000 |
|
- |
|
| Kelley Kenneth J |
Director |
– • – |
2013-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
170,000 |
|
- |
|
| Patton John Stuart |
Director |
– • – |
2013-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
130,000 |
|
- |
|
| Matsui Connie |
Director |
– • – |
2013-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
145,000 |
|
- |
|
| Engler Robert L Md |
Director |
– • – |
2013-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
185,000 |
|
- |
|
| Posard Matthew L. |
Director |
– • – |
2013-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Shepard H. Michael |
VP, Chief Scientific Officer |
• – – |
2013-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,798 |
23,198 |
|
- |
|
| Frost Gregory Ian |
CEO, President |
• • – |
2013-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,049 |
3,571,380 |
|
- |
|
| Shaffer James P |
VP & Chief Commercial Officer |
• – – |
2013-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,232 |
37,532 |
|
- |
|
| Liu Jean I |
VP & General Counsel |
• – – |
2013-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,827 |
7,827 |
|
- |
|
| Gustafson Kurt A |
Vice President and CFO |
• – – |
2013-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,467 |
35,667 |
|
- |
|
| Engler Robert L Md |
Director |
– • – |
2012-11-29 |
4 |
B |
$5.57 |
$83,550 |
D/D |
15,000 |
165,000 |
2.39 |
- |
|
| Shaffer James P |
VP & Chief Commercial Officer |
• – – |
2012-11-14 |
4 |
B |
$5.22 |
$104,400 |
D/D |
20,000 |
26,300 |
2.74 |
- |
|
| Falberg Kathryn E |
Director |
– • – |
2012-11-13 |
4 |
B |
$5.21 |
$260,500 |
D/D |
50,000 |
160,000 |
2.39 |
- |
|
| Kelley Kenneth J |
Director |
– • – |
2012-08-27 |
4 |
B |
$5.70 |
$113,974 |
D/D |
20,000 |
150,000 |
2.39 |
- |
|
| Frost Gregory Ian |
CEO, President |
• • – |
2012-08-13 |
4 |
B |
$5.50 |
$11,000 |
D/D |
2,000 |
3,555,331 |
2.81 |
- |
|
| Kirk Randal J |
Director |
– • • |
2012-06-05 |
4 |
B |
$7.48 |
$40,863 |
I/I |
5,463 |
331,394 |
2.25 |
- |
|
| Kirk Randal J |
Director |
– • • |
2012-06-04 |
4 |
B |
$7.37 |
$660,691 |
I/I |
89,646 |
328,663 |
2.25 |
- |
|
| Kirk Randal J |
Director |
– • • |
2012-06-01 |
4 |
B |
$7.39 |
$732,201 |
I/I |
99,080 |
283,840 |
2.25 |
- |
|
| Kirk Randal J |
Director |
– • • |
2012-05-17 |
4 |
B |
$7.50 |
$2,242,553 |
I/I |
299,007 |
3,977,445 |
2.25 |
- |
|
| Kirk Randal J |
Director |
– • • |
2012-05-16 |
4 |
B |
$7.44 |
$2,566,130 |
I/I |
344,910 |
3,678,438 |
2.25 |
- |
|
| Kirk Randal J |
Director |
– • • |
2012-05-15 |
4 |
B |
$7.35 |
$3,142,720 |
I/I |
427,581 |
3,333,528 |
2.25 |
- |
|
| Shepard H. Michael |
VP, Chief Scientific Officer |
• – – |
2012-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,400 |
11,400 |
|
- |
|
| Frost Gregory Ian |
CEO, President |
• • – |
2012-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,465 |
3,553,331 |
|
- |
|
839 Records found
|
|
Page 22 of 34 |
|
|
0.94 (2.17%) 
